Chinese Biotech Financing Rebounds But Mega Deals Missing

Ten Chinese biotechs raised at least a combined $221m in venture capital and private equity deals after the turn of the year.

funding
The $100m mark was still out of reach for most Chinese biotechs seeking funds. • Source: Shutterstock

Mega-sized financing deals backed by venture capital and private equity firms have bypassed Chinese biotechs, since a string of transactions worth $100m impressed the sector around the turn of the year. (Also see "Latest Big Rounds Herald A China Biotech Funding Spring?" - Scrip, 18 January, 2023.)

Nearing the $100m mark was Immorna Biotherapeutics, Inc., which focuses on the development of messenger RNA-based therapeutics and vaccines....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

More from Focus On Asia

Sun’s Alopecia Treatment Debuts In US - Can It Make Up For Lost Time?

 

Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?

Activist Investor Vs. Japan Pharma: ASKA Plans Poison Pill As Dalton Pushes For MBO

 
• By 

While ASKA plans to dilute the holding of largest investor Dalton by issuing new shares, the US investment firm continues to push a management buyout option to the mid-sized Japanese pharma company.

China’s Mid-Cap Companies Thriving On Big Pharma Deals

 

Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.